The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

Eli Lilly has announced a strategic collaboration with UK government departments to address population health challenges, ...

Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year ...

Europe is seemingly cracking down on weight-loss drugs like Wegovy; but the French agency cited deductive reasoning, ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

The one problem Lilly has faced is meeting the soaring demand for these products. In fact, they are so popular that the U.S.